PHS
ACLX

PFM Health Sciences’s Arcellx ACLX Stock Holding History

PFM Health Sciences’s Portfolio ACLX Stock Details ACLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15,488
Closed -$1.02M – 58
2025
Q1 		$1.02M Sell
15,488
-41,115
-73% -$2.79M 0.07% 60
2024
Q4 		$4.34M Sell
56,603
-3,999
-7% -$345K 0.27% 57
2024
Q3 		$5.06M Sell
60,602
-251,378
-81% -$16.7M 0.29% 52
2024
Q2 		$17.2M Buy
311,980
+8,770
+3% +$477K 0.85% 36
2024
Q1 		$21.1M Sell
303,210
-31,988
-10% -$2.03M 0.99% 36
2023
Q4 		$18.6M Buy
335,198
+94,860
+39% +$4.28M 1.12% 32
2023
Q3 		$8.62M Sell
240,338
-15,494
-6% -$534K 0.41% 56
2023
Q2 		$8.09M Sell
255,832
-269,984
-51% -$10.3M 0.31% 61
2023
Q1 		$16.2M Sell
525,816
-90,699
-15% -$2.75M 0.72% 48
2022
Q4 		$19.1M Buy
+616,515
New +$14.1M 0.68% 54

Other funds holding ACLX

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

PFM Health Sciences's ACLX Position: Q2 2025 in Review

PFM Health Sciences sold out of Arcellx (ACLX) in Q2 2025, closing a stake of 15,488 shares — an estimated $1.02M sold.

PFM Health Sciences first reported a position in ACLX in Q4 2022 and held it in 10 quarters. The position peaked at $21.1M in Q1 2024. 202 funds tracked by Wall St. Rank hold ACLX as of Q2 2025.

  • PFM Health Sciences reported no remaining Arcellx position as of Q2 2025 after selling out during the quarter.
  • PFM Health Sciences sold 15,488 Arcellx shares in Q2 2025, an estimated $1.02M.
  • PFM Health Sciences first reported a position in Arcellx in Q4 2022 and held it in 10 quarters.
  • PFM Health Sciences's Arcellx position peaked at $21.1M in Q1 2024.
  • 202 funds tracked by Wall St. Rank held Arcellx as of Q2 2025.

Based on PFM Health Sciences's 13F filing for Q2 2025, filed 14 Aug 2025.